Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.27 USD | +6.22% | +3.89% | -22.36% |
Apr. 30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
Mar. 27 | North American Morning Briefing : Stocks Edge -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 35.83M |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -31M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.14
x | P/E ratio 2025 * |
-3.14
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.85% |
Latest transcript on Marker Therapeutics, Inc.
1 day | +4.48% | ||
1 week | +3.89% | ||
Current month | +5.43% | ||
1 month | -9.34% | ||
3 months | +5.43% | ||
6 months | +40.09% | ||
Current year | -22.36% |
Managers | Title | Age | Since |
---|---|---|---|
Juan F. Vera
CEO | Chief Executive Officer | 44 | 18-10-16 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 18-10-16 | |
Steven Elms
BRD | Director/Board Member | 60 | 19-08-05 |
Katharine Knobil
BRD | Director/Board Member | 60 | 21-12-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 4.27 | +6.22% | 8 765 |
24-05-07 | 4.02 | -2.19% | 13,477 |
24-05-06 | 4.11 | -2.61% | 13,065 |
24-05-03 | 4.22 | +0.48% | 13,189 |
24-05-02 | 4.2 | +2.19% | 2,242 |
Delayed Quote Nasdaq, May 08, 2024 at 01:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.36% | 35.83M | |
+22.25% | 46.4B | |
-1.75% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+9.86% | 26.01B | |
-19.30% | 19.52B | |
+29.41% | 12.43B | |
-0.01% | 12.18B | |
-0.73% | 12.13B |
- Stock Market
- Equities
- MRKR Stock